{"id":494232,"date":"2021-05-17T08:34:34","date_gmt":"2021-05-17T12:34:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-clinical-data-showing-significant-and-sustained-reduction-in-systolic-blood-pressure-out-to-two-years-with-backbeat-cardiac-neuromodulation-therapy\/"},"modified":"2021-05-17T08:34:34","modified_gmt":"2021-05-17T12:34:34","slug":"orchestra-biomed-announces-clinical-data-showing-significant-and-sustained-reduction-in-systolic-blood-pressure-out-to-two-years-with-backbeat-cardiac-neuromodulation-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-clinical-data-showing-significant-and-sustained-reduction-in-systolic-blood-pressure-out-to-two-years-with-backbeat-cardiac-neuromodulation-therapy\/","title":{"rendered":"Orchestra BioMed\u2122 Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy\u2122"},"content":{"rendered":"
\n

\n Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to two years<\/em>\n <\/p>\n

\n 88% of the treated patients had isolated systolic hypertension (ISH)<\/em>\n <\/p>\n

\n 70.6% of all treated patients and 80% of treated ISH patients had their blood pressure under control at 24 months<\/em>\n <\/p>\n

NEW HOPE, Pa., May 17, 2021 (GLOBE NEWSWIRE) — Orchestra BioMed\u2122<\/sup>, Inc., (\u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine, presented interim two-year data on its MODERATO II patients treated with BackBeat Cardiac Neuromodulation Therapy\u2122<\/sup>\u00a0on May 15th<\/sup>, 2021 at the virtual American College of Cardiology (ACC) Meeting. The data demonstrated a clinically meaningful and statistically significant reduction of 16.6 mmHg in office Systolic Blood Pressure (oSBP) that was sustained out to two years.<\/p>\n

\u201cThese data provide evidence of significant long-term reductions in systolic blood pressure with a lower-than-expected rate of major cardiac events when BackBeat CNT is activated for a period of up to two years,\u201d stated Daniel Burkhoff, M.D., Ph.D., Director of Heart Failure, Hemodynamics and MCS Research at the Cardiovascular Research Foundation. \u201cOf clinical significance is the fact that the majority of the patients in the MODERATO II study had ISH.\u00a0 In these patients, a significant reduction in systolic blood pressure with minimal effect on diastolic blood pressure is ideal and is difficult to achieve with antihypertensive medications.\u00a0 Furthermore, 80% of the ISH patients in MODERATO II had their blood pressure under control at 24 months, which could translate to meaningful reductions in cardiovascular events.\u201d<\/p>\n

MODERATO II is a European prospective, multi-center, double-blind, randomized study of BackBeat CNT (n=26) vs. control (n=21) in patients with persistent hypertension (ASBP \u2265130 mmHg and oSBP \u2265 140 mmHg) despite one or more anti-hypertensive medications and a pacemaker indication. Of the 26 treatment patients, 25 completed 18 months of follow-up (one patient died of cancer) and 17 reached 24 months of therapy to date. Key interim study data:<\/p>\n